China’s Mabworks Biotech Raises US$160M in Two Series C Rounds

China’s Mabworks Biotech Raises US$160M in Two Series C Rounds

The company develops therapeutic antibodies via integrated technology.

Beijing-based biotech and pharmaceutical company Beijing Mabworks Biotech announced that it had raising funding up to RMB 1.13 billion (US $160 million) in its Series C1 and C2, DealStreetAsia reported today.

The capital will be used to strengthen Mabworks’ research and development efforts, and commercialize its macromolecule drugs.

The round was led by CICC Qide Innovative Biopharmaceutical Equity Investment Fund, CITIC Securities, healthcare-focused fund Lyzz Capital, and Huge Capital, the report said.

CICC Capital, the investment arm of state-owned Chinese investment bank China International Corporation Limited, acted as an advisor to the deal.

Among others, Bank of Communications’ subsidiary BOCOM International, Beijing E-Town International Investment & Development, SDIC Unity Capital, Yuexiu Financial Holdings’ Industrial Fund, and Sealand Innovation participated in the round.

Other investors of the company include GTJA Investment Group, Medfine Capital, QS Capital, and Beijing Yizhuang Biomedical Fund, from whom Mabworks previously raised funds in 2016, according to the report.

“We will further expedite our capacity in the emerging market, to provide affordable drugs for Chinese patients suffering from cancers and autoimmune diseases. Also, we do expect we can be more competitive by navigating the advantages in macromolecules research and partnerships with institutions,” Mabworks’ Chairman and President Dr Feng Li said in the company’s statement.

Mabworks is a clinical stage biopharma company that develops antibody medication. It uses integrated technology platforms to develop, manufacture and commercialize therapeutic antibodies. The company says that it has over 50 patents in and out of China.

Mabworks has developed over 15 biomedical assets through clinical trials in China and the United States. Their solutions cover various critical illnesses such as lung cancer, breast cancer, colorectal cancer, leukaemia, and infectious diseases. Additionally, the biopharmaceutical venture has collaborated with oncology and autoimmune diseases drug maker InnoCare Pharma to develop a novel therapy for B-cell lymphoma, the report mentioned.

The company’s previous funding round was a Series B in January 2017, according to Crunchbase data. Mabworks raised RMB 270 million (about US$38 million) in the round.

Private equity firm GTJA Investment Group acted as the lead investor in the Series B which also saw participation from Shanghai-based investment firm MF Capital and Hong Kong-based Harvest Global Investment.

Crunchbase data also shows that MF Capital led the 2003-founded Mabworks’ Series A for RMB 100 million (about US $14 million) in 2016.

Header image by Bill Oxford on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email
Sharon Lewis
Sharon is a Staff Writer at Jumpstart

RELATED POSTS

How to Invest in the Cannabis Industry

How to Invest in the Cannabis Industry

Despite cannabis (also known as weed or marijuana) being illegal in a large part of the world, the global cannabis market was worth US$28.26 billion in 2021 and is expected to grow to US$197.74 billion by 2028. Gone are the days when venture capital firms would dismiss cannabis companies as problematic investments.

Why Crypto Markets Crash and 5 Ways Investors Can Deal

Why Crypto Markets Crash and 5 Ways Investors Can Deal

With more and more people holding cryptocurrencies today, the crypto crash of May 2022 has had severe financial consequences. Reliable currencies, including Bitcoin and Ether, met a terrible fate, as did stablecoins, amounting to losses of over US$300 billion.

How Lemi Is Helping Small Businesses Reach Their Customers

How Lemi Is Helping Small Businesses Reach Their Customers

Starting a business isn’t easy. From finding raw materials and making your products to actually reaching the right customer base, everything takes a lot of time and energy. Even though this process is so hard, a lot of people venture out and start their own businesses, so much so that small business enterprises (SMEs) make up 90% of the world’s businesses.

What Is CateCoin and Is It Legit

What Is CateCoin and Is It Legit?

At a time when meme coins, like Dogecoin and Shiba Inu, are enjoying immense popularity, another cryptocurrency has been laying the groundwork to compete with them: CateCoin.

Companies that Might Accept Crypto Payments in 2022

Companies that Might Accept Crypto Payments in 2022

The cryptocurrency industry is growing rapidly, and with that growth comes increased interest from companies looking to accept crypto payments. While there are already a few major companies that accept cryptocurrency payments, like Microsoft and PayPal, many more are considering following suit.